For the Inventor, By the Inventor

Enter assignee name

Fondation Imagine

USPTO Granted Patents = 15

% Expired Patents = 20.0

EPO Patents = 17

Forward Citations = 4

Loading Chart...

Loading Chart...

59 inventors (with patents filed for the assignee):

Olivier Hermine (7 out of 15 patents)

Flavia Guillem (3 out of 3 patents)

Jean-Benoit Arlet (3 out of 3 patents)

4. Laurence Legeai-Mallet (2 out of 4 patents)

5. Arnold Munnich (2 out of 12 patents)

6. Zakia Belaid-Choucair (2 out of 2 patents)

7. Carmen Garrido-Fleury (2 out of 3 patents)

8. Renaud Seigneuric (2 out of 3 patents)

9. Genevieve Courtois (2 out of 2 patents)

10. Antonio Segura Carretero (2 out of 2 patents)

11. Maria De La Luz Cadiz Gurrea (2 out of 2 patents)

12. Leila Maouche-Chretien (1 out of 1 patent)

13. Christine Bodemer (1 out of 2 patents)

14. Laura Polivka (1 out of 1 patent)

15. David Bikard (1 out of 21 patents)

15 patents: Sort by Forward Citations

1. 12668812 - RECOMBINANT VECTORS SUITABLE FOR THE TREATMENT OF IPEX SYNDROME (2026-06-30),

2. 12257232 - Methods and pharmaceutical compositions for the treatment of FGFR3-related chondrodysplasias (2025-03-25),

3. 11951090 - Methods and pharmaceutical compositions for the treatment of FGFR3-related chondrodysplasias (2024-04-09),

4. 11857532 - Treatment and prediction of therapeutic responses in patients suffering from Friedreich ataxia (2024-01-02),

5. 11725183 - Method of culturing segmented filamentous bacteria in vitro (2023-08-15),

6. 11667913 - Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof (2023-06-06),

7. 11629192 - Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway (2023-04-18),

8. 11389434 - Methods and pharmaceutical compositions for the treatment of mast cell diseases (2022-07-19),

9. 11065230 - Methods and pharmaceutical compositions for the treatment of systemic mastocytosis (2021-07-20),

10. 10653687 - Methods and pharmaceutical compostions for treating rhabdomyolysis (2020-05-19),

11. 10647752 - Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1 (2020-05-12),

12. 10435665 - Method of culturing segmented filamentous bacteria in vitro (2019-10-08),

13. 9861615 - Methods and pharmaceutical compositions for the treatment of beta-thalassemias (2018-01-09),

14. 9675590 - Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes (2017-06-13),

15. 9377471 - Methods and compositions for the treatment of β-thalassemia (2016-06-28),

Company Overview

Fondation Imagine, based in Paris, is dedicated to advancing research in the field of genetic diseases. The foundation focuses on fostering innovation and collaboration among scientists, clinicians, and industry partners to develop new therapeutic approaches. Its primary research domains include genomics, molecular biology, and personalized medicine, aiming to translate scientific discoveries into tangible health solutions. By supporting interdisciplinary projects, Fondation Imagine plays a pivotal role in enhancing the understanding and treatment of complex genetic disorders.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

15 Patents

#285 in Paris

#1,259 in France

#39,959 in the World

Fondation Imagine

Forward Citations = 4

59 inventors:

Olivier Hermine (7 out of 15 patents)

Flavia Guillem (3 out of 3 patents)

Jean-Benoit Arlet (3 out of 3 patents)

4. Laurence Legeai-Mallet (2 out of 4 patents)

5. Arnold Munnich (2 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Fondation Imagine. Retrieved from https://idiyas.com/company/fondation-imagine

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…